Medical Management with HBOC

If BRACAnalysis® testing confirms the presence of a BRCA1 or BRCA2 mutation, the following medical management options may help reduce cancer risk and may either delay the onset of cancer, detect cancer at an earlier, more treatable stage or even prevent it.*

Increased Surveillance for Breast Cancer in Mutation Carriers

  • Monthly breast self-exams starting at age 18 12
  • Annual or semiannual clinical breast exams starting at age 25 13
  • Yearly mammography starting at age 25 12,13
  • Yearly magnetic resonance imaging (MRI) starting at age 25 or individualized based on earliest case in the family 12,14

Increased Surveillance for Ovarian Cancer in Mutation Carriers

  • Annual or semiannual transvaginal ultrasound 12,13
  • Annual of semiannual blood test for CA125 beginning at age 2512,13
  • Annual pelvic exams

Risk Reducing Medications for Mutation Carriers

  • Tamoxifen use has been associated with a reduction of 53% in the risk of a second primary breast cancer in contralateral cancers 15
  • Oral contraceptives, when taken for 6 or more years, have been associated with a reduction of up to 60% in the risk of ovarian cancer 16

Prophylactic Surgery in Mutation Carriers

  • Prophylactic mastectomy reduces breast cancer risk by at least 90% 17
  • Prophylactic oophorectomy reduces ovarian cancer risk by up to 96% and breast cancer risk by up to 68% 18,19
* Any discussion of medical management options is for general informational purposes only and does not constitute a recommendation.  While genetic testing and medical society guidelines provide important and useful information, medical management decisions should be made based on consultation between each patient and his or her healthcare provider.
^ HBOC Syndrome management is an evolving area.  The most up to date management guidelines from NCCN can be found at the National Comprehensive Cancer Network.  See the Genetic/Familial High-Risk Assessment: Breast and Ovarian guidelines.